• 26087 Citations
  • 66 h-Index

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

  • 26087 Citations
  • 66 h-Index
  • 291 Article
  • 8 Review article
  • 2 Comment/debate
  • 2 Letter

Repotrectinib (Tpx-0005) is a next-generation ros1/trk/alk inhibitor that potently inhibits ros1/trk/alk solvent-front mutations

Drilon, A., Ou, S. H. I., Cho, B. C., Kim, D. W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M. J., Camidge, D. R., Nguyen, J., Zhai, D., Deng, W., Huang, Z., Rogers, E., Liu, J., Whitten, J., Lim, J. K., Stopatschinskaja, S., Hyman, D. M., Doebele, R. C. & 2 others, Cui, J. J. & Shaw, A. T., Oct 2018, In : Cancer Discovery. 8, 10

Research output: Contribution to journalComment/debate

66 Scopus citations

Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056

Kim, H. R., Jang, J. S., Sun, J. M., Ahn, M. J., Kim, D-W., Jung, I., Lee, K. H., Kim, J. H., Lee, D. H., Kim, S. W. & Cho, B. C., 2017, In : Oncotarget. 8, 33, 1 p.

Research output: Contribution to journalComment/debate